Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease

Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function

“…[20][21][22] Importantly, they also experience significant dyshomeostasis in lipid metabolism, leading to potentially modifiable atherosclerotic risks, including poor clearance of circulating triglycerides and lipoproteins, reduced lipoprotein lipase activity, increased oxidation of LDL cholesterol, and possibly, increased relative cholesterol absorption. [23][24][25][26] In the IMPROVE-IT, compared with simvastatin monotherapy, individuals randomized to combination therapy with ezetimibe plus simvastatin experienced a greater mean reduction in both LDL cholesterol and triglycerides across all levels of eGFR. Because individuals with CKD are an inherently higher-risk group, achieving the same absolute level of reduction in LDL cholesterol through both inhibition of cholesterol synthesis and cholesterol absorption may be more effective in risk mitigation; however, considering the numerous mechanisms by which CKD leads to increased cardiovascular risk, the relative benefit that we observed from combination therapy as eGFR declined could also suggest that ezetimibe add-on therapy conferred pleiotropic effects beyond LDL cholesterol or triglyceride reduction alone.…”

A Novel Mutation ApoE2 Kurashiki (R158P) in a Patient with Lipoprotein Glomerulopathy

“…A recent report suggested that early diagno- . As discussed, LPG is a genetic kidney disease, but with a lipoprotein profile 17) similar to that of chronic kidney disease (CKD), and shows increases of serum triglycerides, VLDL and IDL 18) ; therefore, LPG analysis might be important for identifying the relationship between dyslipidemia and various other kidney diseases. We expect that additional cases of LPG will contribute to revealing the pathophysiology of the relationship between CKD and lipoproteins as well as of LPG itself.…”

A Ten Year Overview of Surgical and Interventional Arrhythmology in Russia. Service Peculiar Features in the Far East

“…ХБП характеризуется смешанной дислипидемией (высокие уровни триглицеридов и ХС-ЛПНП, низкая кон-центрация ХС-ЛПВП) [492] . Микроальбуминурия является фактором риска развития ССЗ, который прогрессивно нарастает от нормальной СКФ до терминальной почечной недостаточности .…”